Navigation Links
Ad hoc: Interim report about clinical trial of BF-200 ALA in,actinic keratosis

LEVERKUSEN, Germany, 30 April 2007 - Biofrontera AG announced that an interim report regarding the clinical study of BF-200 ALA in actinic keratosis was received today from an independent review committee. The objectives of the study are to investigate the efficacy and safety of several doses of BF-200 ALA in photodynamic therapy. The comments received today refer to the clinical results eight weeks after treatment. An additional report about the results after twelve weeks will follow.

The interim committee reported that no side effect justifying concerns about the safety of this dose were observed in any dose group. On the basis of the available data, the therapy was found to be safe for all doses tested.

In spite of the limited patient number, different doses gave rise to clear differences in efficacy. However, the results of the different doses were not yet disclosed. The committee announced this disclosure once it has received and analyzed the clinical results 12 weeks after treatment. Biofrontera expects this second report within few weeks.

To optimize the statistical study design, the committee has proposed to continue the phase III part of the study separately. This will enable the complete analysis of the 12-week data. On this basis, Biofrontera intends to continue the further development of the 10 % dose, provided this dose selection is supported by the 12-week data.

Biofrontera AG Hemmelrather Weg 201, 51377 Leverkusen, Germany ISIN: DE0006046113 WKN: 604611

Contact: Anke zur Mühlen Biofrontera AG Tel.: +49 (0214) 87 63 222 Fax.: +49 (0214) 87 63 290 e-mail: a.zurmuehlen@biofrontera.com


'"/>




Page: 1

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
3. Ablynx Announces Interim Results of First Nanobody Phase I Study of ALX-0081 (ANTI-VWF)
4. Based on Up to 6 Years of Follow-Up, Biovest Announces Favorable Interim Blinded Data for Fast-Tracked Pivotal Phase 3 Clinical Trial of BiovaxID Anti-Cancer Vaccine for Non-Hodgkins Lymphoma
5. ZIO-101 (Darinaparsin) Interim Phase II and Preclinical Data Presented at International Myeloma Workshop
6. Accentia Biopharmaceuticals Announces Favorable Interim Blinded Data on SinuNase in Its Fast-Tracked Pivotal Phase 3 Clinical Trial for Chronic Sinusitis
7. Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer
8. Interim Analysis of Crinone Pregnancy Study to Be Published in American Society for Reproductive Medicine Journal
9. Avalon Pharmaceuticals Announces Positive Interim Results For AVN944 Phase I Trial
10. Vical Interim Clinical Results Demonstrate Safety and Tolerability of Inovio Biomedicals Electroporation DNA Delivery Technology
11. Interim Data From RECORD Study Show No Significant Difference Between Avandia and Standard Therapy in Risk of Cardiovascular Hospitalization or Death
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2017)... Research and Markets has announced the addition ... their offering. ... The global lifestyle drugs market to grow at a CAGR of ... Lifestyle Drugs Market 2017-2021, has been prepared based on an in-depth ... market landscape and its growth prospects over the coming years. The ...
(Date:3/29/2017)... Calif. , March 29, 2017 Varian Medical ... will report results for the second quarter of fiscal year ... 26, 2017.  The news release will be followed by a ... The news release and a link to the conference call ... www.varian.com/investor .  To access the teleconference call and replay: ...
(Date:3/29/2017)... Calif. , March 29, 2017  Designers of ... significantly reduce solution size by 50% and extend battery ... ) power management integrated circuit (PMIC) from Maxim Integrated ... PMIC supports a low input voltage of just 0.7V ... Air and Silver Oxide, as well as the more ...
Breaking Medicine Technology:
(Date:3/30/2017)... ... ... from Greet, S.C., wants to offer people a new way to care for their feet. ... so I know the importance of proper foot care," he said. "In order to enable ... The FOOT-TRAN SYSTEM enables a user to clean and exfoliate the bottoms of his or ...
(Date:3/30/2017)... Washington, DC (PRWEB) , ... March 30, 2017 ... ... scientists and organizations submitted a letter to President Trump expressing their support for ... two medical doctors, two Ph.D. scientists and one medical journalist, will hold a ...
(Date:3/29/2017)... ... March 29, 2017 , ... In the United States alone, ... each year develop other types of metastatic brain tumors(3). Though most meningiomas are benign, ... efforts focus on finding more effective treatment options, the San Diego Gamma Knife ...
(Date:3/29/2017)... ... 30, 2017 , ... Grass pollen is the main cause of hay fever in the United ... for grass pollen runs from May to July each year; with the worst time for ... HayMax™ allergen barrier balms ( http://www.haymax.us ) provide an effective defense against grass pollen; they ...
(Date:3/29/2017)... ... March 30, 2017 , ... Sublime Naturals and its founder, Kathy Heshelow, are ... it has been used for thousands of years. , "The West has caught on, ... " Turmeric: How to Use it For Your Wellness. Overcome Inflammation, Enemy of the ...
Breaking Medicine News(10 mins):